- Home
- SAIH vs SYBX Comparison
SAIH vs SYBX Comparison
Compare SAIH & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAIH
- SYBX
- Stock Information
- Founded
- SAIH 2019
- SYBX N/A
- Country
- SAIH Singapore
- SYBX United States
- Employees
- SAIH N/A
- SYBX N/A
- Industry
- SAIH
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- SAIH
- SYBX Health Care
- Exchange
- SAIH NYSE
- SYBX Nasdaq
- Market Cap
- SAIH 13.4M
- SYBX 13.6M
- IPO Year
- SAIH N/A
- SYBX N/A
- Fundamental
- Price
- SAIH $5.74
- SYBX $1.14
- Analyst Decision
- SAIH
- SYBX
- Analyst Count
- SAIH 0
- SYBX 0
- Target Price
- SAIH N/A
- SYBX N/A
- AVG Volume (30 Days)
- SAIH 61.3K
- SYBX 11.5K
- Earning Date
- SAIH 04-28-2025
- SYBX 05-20-2025
- Dividend Yield
- SAIH N/A
- SYBX N/A
- EPS Growth
- SAIH N/A
- SYBX N/A
- EPS
- SAIH N/A
- SYBX 0.21
- Revenue
- SAIH $5,543,000.00
- SYBX N/A
- Revenue This Year
- SAIH N/A
- SYBX N/A
- Revenue Next Year
- SAIH N/A
- SYBX N/A
- P/E Ratio
- SAIH N/A
- SYBX $5.30
- Revenue Growth
- SAIH N/A
- SYBX N/A
- 52 Week Low
- SAIH $3.00
- SYBX $0.90
- 52 Week High
- SAIH $26.99
- SYBX $1.91
- Technical
- Relative Strength Index (RSI)
- SAIH N/A
- SYBX 48.94
- Support Level
- SAIH N/A
- SYBX $1.00
- Resistance Level
- SAIH N/A
- SYBX $1.19
- Average True Range (ATR)
- SAIH 0.00
- SYBX 0.09
- MACD
- SAIH 0.00
- SYBX 0.00
- Stochastic Oscillator
- SAIH 0.00
- SYBX 67.50
About SAIH SAIHEAT LIMITED
Saiheat Ltd develops technologies for the Computing Center Ecosystem (ACCE), a next-gen computing center featuring high-performance servers, liquid cooling, and systems for capturing and recycling computing heat. It aims to reduce the carbon footprint of Bitcoin mining and AI operations. The Company has four reportable segments: equipment sales, hosting, mining pool business, and mining.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.